Unresectable or Metastatic Pancreatic Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Unresectable or Metastatic Pancreatic Cancer Market Outlook

Thelansis’s “Unresectable or Metastatic Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Unresectable or Metastatic Pancreatic Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Unresectable or Metastatic Pancreatic Cancer Overview

Unresectable or metastatic pancreatic cancer (LAPC) is an advanced stage where the tumor cannot be completely removed through surgery or has spread to other body parts. Patients with LAPC often experience significant symptom burdens related to their primary malignancy. These symptoms may include pain, pancreatic insufficiency (resulting in difficulty digesting food), biliary obstruction (causing jaundice and related symptoms), and early satiety or gastric outlet obstruction (leading to feeling full quickly or difficulty eating). Most patients with pancreatic cancer are diagnosed at an advanced stage, with approximately 50% having metastatic disease and 25% to 35% having borderline or locally advanced disease. In terms of treatment options, gemcitabine plus nab-paclitaxel or FOLFIRINOX are commonly used as first-line chemotherapy regimens for patients with locally advanced or metastatic pancreatic cancer. Gemcitabine plus nab-paclitaxel has a median overall survival of 8.5 months, while FOLFIRINOX has a median survival of 11.1 months. Only a small percentage, fewer than 10%, of patients with pancreatic cancer have tumors that are potentially curable through surgical resection.

• In the USA, approximately 64,050 individuals will receive a pancreatic cancer diagnosis, with about 33,130 being men and 30,920 being women. Moreover, around 50,550 will die of pancreatic cancer, comprising 26,620 men and 23,930 women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: